Early outpatient administration of Remdesivir shortens recovery time in patients with mild to moderate COVID-19
| Autor: | Majid Hajimaghsoudi, Fatemeh Saghafi, Mahya Shorabi, Samaneh Mirzaei, Mehrnaz Moharami, Negin Daryaei, Farahnaz Hoseinzade, Farzad Jalili, Hamid Reza Rezaei, Yekta Rameshi, Mohsen Gholinataj Jelodar |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Journal of Pharmaceutical Care, Vol 11, Iss 4 (2023) |
| Druh dokumentu: | article |
| ISSN: | 2322-4630 2322-4509 |
| Popis: | Background During COVID-19, healthcare systems in underdeveloped nations had significant challenges and were unlikely to offer the necessary care. It appears that a new, reliable healthcare model that prevents hospitalization is necessary to reduce the pressure that COVID-19 is putting on healthcare systems and patients. More particularly, as Remdesivir's use as an outpatient treatment for mild to severe SARS-CoV-2 infection has rarely been examined; we aimed to investigate in-depth comprehension of the effects of Remdesivir in these cases. Methods In our two-month cross-sectional study, non-hospitalized patients with mild to moderate COVID-19 who were referred to the hospital for up to 5 days of Remdesivir treatment received 200 mg of Remdesivir intravenously on day 1, followed by 100 mg of Remdesivir once daily for the subsequent 4 days. Patients were divided into groups based on the time of starting Remdesivir treatment after the appearance of symptoms: group 1 less than and equal to 7 days, and group 2 more than 7 days. Two groups were evaluated for a correlation between Remdesivir administration time and clinical symptoms on days 1 and 14 (follow-up visits). Results The study enrolled 273 eligible patients with a mean age of 47.5 years, of whom 112 were males and 125 were females. Results showed that patients who received Remdesivir in the first 7 days had less dyspnea (P-value |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|